It has been proposed that an imbalance between proinflammatory (e.g., interleukin-1β, IL-1β, and tumor necrosis factor α, TNFα) and anti-inflammatory (e.g., IL-4 and IL-10) cytokines with a prevalence of the former, may contribute to brain damage in MS (Linker et al., 2005; Zeis et al., 2008; Ivanov and Lindén, 2009). Here, IL10 is linked to myeloid sarcoma.